Next-Generation Integrated Sequencing Identifies Poor Prognostic Factors in Patients with MYD88-Mutated Chronic Lymphocytic Leukemia in Taiwan
Pathobiology · 2024
DOI: 10.1159/000541709 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathobiology, 2024. Verfasst von Ying-Jung Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Myeloid Differentiation Factor 88, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in the Western countries and is very rare in Asia.
Methods
Peripheral blood or bone marrow mononuclear cells obtained at initial diagnosis from 215 patients with CLL were analyzed by using next-generation sequencing to investigate the ethnic differences in genetic abnormalities.
Results
Whole-genome sequencing and whole-exome sequencing analyses on 30 cases showed that 9 genes, including IGLL5, MYD88, TCHH, DSCAM, AXDND1, BICRA, KMT2D, MYT1L, and RBM43, were more frequently mutated in our Taiwanese cohort compared with those of the Western cohorts. IGLL5, MYD88, and KMT2D genes were further analyzed by targeted sequencing in another 185 CLL patients, unraveling frequencies of 29.3%, 20.9%, and 15.0%, respectively. The most frequent positional mutation of MYD88 was V217F (26/45, 57.8%), followed by L265P (9/45, 20.0%). MYD88 mutations were significantly associated with IGLL5 mutations (p = 0.0004), mutated IGHV (p < 0.0001) and 13q deletion (p = 0.0164). CLL patients with co-occurrence of MYD88 mutations with KMT2D or/and IGLL5 mutations were associated with a significantly inferior survival compared to those with MYD88 mutation alone (not reached vs. 131.8 months, p = 0.007). In multivariate analysis, MYD88 mutation without KMT2D or IGLL5 mutations was an independently favorable predictor.
Conclusions
IGLL5, MYD88, and KMT2D mutations were enriched in Taiwanese CLL, and co-occurrence of MYD88 mutations with KMT2D or/and IGLL5 mutations was associated with a poorer prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
- Lymphoma Genomic Translational Research Laboratory, Division of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore, Singapore.
- ONCO-ACP, Duke-NUS Medical School, Singapore, Singapore.
- Graduate Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University, Taipei, Taiwan.
- School of Medicine, Chang Gung University, Taoyuan, Taiwan.
- Institute of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Taiwan.
Zitieren
APA
Huang, Y. J., Lim, J. Q., Hsu, J. S., Kuo, M. C., Wang, P. N., Kao, H. W., Wu, J. H., Chen, C. C., Tsai, S. F., Ong, C. K., & Shih, L. Y. (2024). Next-Generation Integrated Sequencing Identifies Poor Prognostic Factors in Patients with MYD88-Mutated Chronic Lymphocytic Leukemia in Taiwan. Pathobiology. https://doi.org/10.1159/000541709
Vancouver
Huang YJ, Lim JQ, Hsu JS, Kuo MC, Wang PN, Kao HW, et al. Next-Generation Integrated Sequencing Identifies Poor Prognostic Factors in Patients with MYD88-Mutated Chronic Lymphocytic Leukemia in Taiwan. Pathobiology. 2024. doi:10.1159/000541709
BibTeX
@article{Huang2024,
author = {Huang, Ying-Jung and Lim, Jing Quan and Hsu, Jacob Shujui and Kuo, Ming-Chung and Wang, Po-Nan and Kao, Hsiao-Wen and Wu, Jin-Hou and Chen, Chiu-Chen and Tsai, Shih-Feng and Ong, Choon Kiat and Shih, Lee-Yung},
title = {Next-Generation Integrated Sequencing Identifies Poor Prognostic Factors in Patients with MYD88-Mutated Chronic Lymphocytic Leukemia in Taiwan},
journal = {Pathobiology},
year = {2024},
doi = {10.1159/000541709}
}
EUVIMED